Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies

Complete title: A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects with Hematological Malignancies

Research Study Number 20170102
 
Principal Investigator Ajay Gopal, MD
 
Phase I/II

Research Study Description

This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of eFT508. The study will evaluate oral daily administration of eFT508. Treatment and study subject evaluation will be performed in 21-day cycles.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20170102
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Hematologic Malignancies; Lymphoma

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials